Design and baseline characteristics of the Incremental Decrease in End Points through Aggressive Lipid Lowering study
| Autor: | Terje R. Pedersen, Gary Palmer, Ole Faergeman, John J.P. Kastelein, Mogens Lytken Larsen, Fredrik S. Bendiksen, Anders G. Olsson, Christina Lindahl, Ingar Holme, Matti J. Tikkanen |
|---|---|
| Přispěvatelé: | Amsterdam Cardiovascular Sciences, Vascular Medicine |
| Rok vydání: | 2004 |
| Předmět: |
Adult
Male Simvastatin medicine.medical_specialty Randomization Atorvastatin Coronary Disease 030204 cardiovascular system & hematology law.invention 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Randomized controlled trial law Internal medicine medicine Humans Pyrroles Prospective Studies 030212 general & internal medicine Myocardial infarction Prospective cohort study Aged Aspirin business.industry Cholesterol Anticholesteremic Agents Cholesterol LDL Middle Aged medicine.disease 3. Good health Treatment Outcome chemistry Heptanoic Acids Research Design Cardiology Female lipids (amino acids peptides and proteins) Cardiology and Cardiovascular Medicine business medicine.drug |
| Zdroj: | American journal of cardiology, 94(6), 720-724. Elsevier Inc. |
| ISSN: | 0002-9149 |
| DOI: | 10.1016/j.amjcard.2004.06.003 |
| Popis: | The Incremental Decrease in End Points through Aggressive Lipid Lowering (IDEAL) study is an investigator-initiated trial designed to determine whether additional clinical benefit might be gained through a strategy that decreases levels of low-density lipoprotein cholesterol levels better than those currently achieved with established statin therapy in patients who have coronary heart disease. IDEAL is a multicenter prospective, randomized, open-label, blinded, end point classification study. Patients who had myocardial infarction were randomized to prescription treatment with 80 mg/day of atorvastatin or 20 mg/day of simvastatin (the dose was increased to 40 mg/day at week 24 in those patients whose plasma total cholesterol remained >5.0 mmol/L, or 190 mg/dl, or whose low-density lipoprotein cholesterol remained >3.0 mmol/L, or 115 mg/dl). The primary clinical outcome variable is the time to initial occurrence of a major coronary event, which is defined as nonfatal acute myocardial infarction, coronary death, or resuscitated cardiac arrest. The study is designed to have a power of 90% to detect a relative decrease of 20% in the atorvastatin-group compared with the simvastatin-group in the number of major events caused by coronary heart disease over approximately 5.5 years. The 8,888 randomized patients had the following characteristics: mean age 61.7 +/- 9.5 years, 19.1% women (mean age 64.0 +/- 9.5 years), baseline total cholesterol 5.1 +/- 1.0 mmol/L (197 mg/dl), low-density lipoprotein cholesterol 3.2 +/- 0.9 mmol/L (124 mg/dl), and high-density lipoprotein cholesterol 1.2 +/- 0.3 mmol/L (46 mg/dl). Drug treatment before randomization consisted of statins in 77% of patients, aspirin in 78.9%, beta blockers in 75.1%, and angiotensin-converting enzyme inhibitors in 30% |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect